文献速递眼底病与葡萄膜炎

玻璃体内地塞米松植入剂注射的非药理学方面:3430次注射及并发症的回顾性研究

NONPHARMACOLOGICAL ASPECTS OF INTRAVITREAL DEXAMETHASONE IMPLANT INJECTIONS: A Retrospective Study of 3,430 Injections and Complications.
PubMed 文献 · Retina · 2025-01-01

该回顾性大学研究分析2013至2023年间0.7 mg地塞米松植入剂注射的临床报告,共3430次注射、1471眼、1091例患者。非药理性并发症发生于611次注射(17.8%),结膜下出血最常见(576次,16.8%),威胁视力的非药理性不良事件与并发症35例(1.0%)。作者认为注射的机械影响或植入物位置不当可能导致非药理性并发症,严重者可致视力丧失。

要点

  • 3430次地塞米松植入剂注射中,非药理性并发症发生于611次注射(17.8%)。
  • 结膜下出血是最常见的非药理性并发症(576次,16.8%)。
  • 威胁视力的非药理性不良事件与并发症35例(1.0%),包括前房迁移、玻璃体出血、视网膜脱离、眼内炎、低眼压和植入物位置异常。

核心结论

  • 地塞米松植入剂注射可能因注射的机械影响或植入物位置不当导致非药理性并发症,可能造成视力丧失。
  • 角膜失代偿、视网膜脱离和眼内炎等严重后果可能发生,凸显这些并发症的严重性。
  • 作者认为仔细选择患者并遵循正确的注射技术对降低这些风险至关重要。

研究设计与样本

  • 回顾性大学研究,分析2013至2023年间接受0.7 mg地塞米松植入剂注射患者的临床报告。
  • 共纳入3430次注射,涉及1471眼、1091例患者。
  • 记录患者人口学资料、注射指征和随访数据,纳入注射操作所致并发症及3个月内非药理学副作用的不良事件。

主要发现

  • 非药理性并发症发生于611次注射(17.8%)。
  • 结膜下出血为最主要的非药理性并发症(n=576,16.8%)。
  • 威胁视力的非药理性不良事件与并发症35例(1.0%)。
  • 观察到前房迁移、玻璃体出血、视网膜脱离、眼内炎、低眼压和植入物位置异常等病例。
  • 遇到需要强化治疗和额外手术干预的病例。

临床怎么用

  • 作者认为仔细选择患者并遵循正确的注射技术对降低这些风险至关重要。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This study aims to evaluate the nonpharmacological safety profile of intravitreal dexamethasone implants in cases with different etiologies. METHODS: This retrospective university-based study analyzed clinical reports of patients receiving 0.7 mg dexamethasone implant injections between 2013 and 2023. The study recorded patient demographics, injection indications, and follow-up data. Complications caused by the injection procedure and adverse events other than pharmacological side effects within a 3-month period were included. RESULTS: In this study, 3,430 dexamethasone implant injections were made into 1,471 eyes of 1,091 patients. Nonpharmacological complications developed in 611 injections (17.8%). Subconjunctival hemorrhage was noted as the leading nonpharmacological complication (n = 576, 16.8%). Sight-threatening 35 nonpharmacological adverse events and complications (1.0%) were recorded. Cases of anterior chamber migration, vitreous hemorrhage, retinal detachment, endophthalmitis, hypotony, and implant misplacement were observed. Cases requiring intensive treatments and additional surgical interventions were encountered. CONCLUSION: The injection of the dexamethasone implant may lead to nonpharmacological complications caused by the mechanical impact of the injection or improper positioning of the implant, potentially resulting in vision loss. Severe outcomes such as corneal decompensation, retinal detachment, and endophthalmitis can ensue, emphasizing the gravity of these complications. Careful selection of patients and adherence to proper injection techniques are essential in reducing these risks.

来源:Retina,查看原文。版权归原作者所有。

引用

  1. Kiristioglu MO, Ucan Gunduz G, Abdullayeva N, et al. NONPHARMACOLOGICAL ASPECTS OF INTRAVITREAL DEXAMETHASONE IMPLANT INJECTIONS: A Retrospective Study of 3,430 Injections and Complications. Retina. 2025. PMID: 39312882. doi:10.1097/IAE.0000000000004270

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。